[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:glypican-3":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Glypican-3",12,10,[8,16,23,29,35,41,47,53,59,65,71,78],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04864054","GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:40.683658Z","2026-06-16T05:54:07.907593Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06815432","GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma",[20],"Phase 1","2026-08-26T02:15:13.282904Z","2026-05-05T02:43:29.133664Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06726161","Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC",[12],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:27.948834Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06795022","First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:27.945446Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05003895","GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies",[20],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:27.669007Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07164313","A Study of ZW251 in Participants With Advanced Solid Tumors",[20],"2026-08-26T02:18:20.384845Z","2026-05-05T02:43:29.384442Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06198296","Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells",[20],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:29.711287Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT07148050","Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells",[20],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:29.698343Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT04715191","Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors",[20],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:27.425045Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT06764316","A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer",[20],"2026-08-26T02:17:03.534765Z","2026-06-18T12:24:03.101437Z",{"nct_id":72,"title":73,"phases":74,"status":75,"updated_at":76,"content_modified":77},"NCT07513194","GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)",[20],"NOT_YET_RECRUITING","2026-08-26T02:17:47.813245Z","2026-05-05T02:43:27.948756Z",{"nct_id":79,"title":80,"phases":81,"status":75,"updated_at":82,"content_modified":83},"NCT07224568","Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors",[20],"2026-08-26T02:15:28.524219Z","2026-05-05T02:43:26.899812Z"]